JP7781768B2 - 神経学的および精神障害の治療方法 - Google Patents

神経学的および精神障害の治療方法

Info

Publication number
JP7781768B2
JP7781768B2 JP2022562531A JP2022562531A JP7781768B2 JP 7781768 B2 JP7781768 B2 JP 7781768B2 JP 2022562531 A JP2022562531 A JP 2022562531A JP 2022562531 A JP2022562531 A JP 2022562531A JP 7781768 B2 JP7781768 B2 JP 7781768B2
Authority
JP
Japan
Prior art keywords
compound
disorder
patient
baseline
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523569A5 (enExample
JP2023523569A (ja
Inventor
エイ ボーエン，キャリー
キャボット ホプキンス，セス
エム サイナン，コリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sumitomo Pharma America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma America Inc filed Critical Sumitomo Pharma America Inc
Publication of JP2023523569A publication Critical patent/JP2023523569A/ja
Publication of JP2023523569A5 publication Critical patent/JP2023523569A5/ja
Priority to JP2025203646A priority Critical patent/JP2026035701A/ja
Application granted granted Critical
Publication of JP7781768B2 publication Critical patent/JP7781768B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022562531A 2020-04-14 2021-04-13 神経学的および精神障害の治療方法 Active JP7781768B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203646A JP2026035701A (ja) 2020-04-14 2025-11-26 神経学的および精神障害の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063009595P 2020-04-14 2020-04-14
US63/009,595 2020-04-14
US202063039722P 2020-06-16 2020-06-16
US63/039,722 2020-06-16
PCT/US2021/026953 WO2021211489A1 (en) 2020-04-14 2021-04-13 (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203646A Division JP2026035701A (ja) 2020-04-14 2025-11-26 神経学的および精神障害の治療方法

Publications (3)

Publication Number Publication Date
JP2023523569A JP2023523569A (ja) 2023-06-06
JP2023523569A5 JP2023523569A5 (enExample) 2024-04-23
JP7781768B2 true JP7781768B2 (ja) 2025-12-08

Family

ID=75787267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562531A Active JP7781768B2 (ja) 2020-04-14 2021-04-13 神経学的および精神障害の治療方法
JP2025203646A Pending JP2026035701A (ja) 2020-04-14 2025-11-26 神経学的および精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203646A Pending JP2026035701A (ja) 2020-04-14 2025-11-26 神経学的および精神障害の治療方法

Country Status (12)

Country Link
US (2) US11738002B2 (enExample)
EP (2) EP4736951A2 (enExample)
JP (2) JP7781768B2 (enExample)
KR (1) KR20230003503A (enExample)
CN (1) CN115734785A (enExample)
AU (1) AU2021257786A1 (enExample)
CA (1) CA3180115A1 (enExample)
DK (1) DK4135690T3 (enExample)
IL (1) IL297248A (enExample)
MX (1) MX2022012833A (enExample)
WO (1) WO2021211489A1 (enExample)
ZA (1) ZA202211311B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CN114377007A (zh) * 2022-02-23 2022-04-22 江苏海洋大学 一种度洛西汀与sep-363856联用用于制备治疗抑郁症的药物组合物
US12400766B1 (en) 2022-07-22 2025-08-26 Veeva Systems Inc. Systems and methods for electronically collecting and linking standardized case data in a data warehouse
AU2023334027A1 (en) * 2022-08-30 2025-01-09 Sumitomo Pharma America, Inc. Ulotaront for the adjuvant treatment of major depressive disorder
EP4601634A1 (en) 2022-10-13 2025-08-20 Sumitomo Pharma America, Inc. Methods of reducing physical dependence to neuropsychiatric treatments
AU2023367071A1 (en) * 2022-10-28 2025-06-12 Sumitomo Pharma America, Inc. Ulotaront for treating anxiety and associated conditions
TW202600129A (zh) * 2024-02-23 2026-01-01 美商住友製藥美國公司 烏洛托隆（ulotaront）鹽酸鹽的製造方法
WO2025252814A1 (en) 2024-06-04 2025-12-11 Duc Duy Vo Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507602A (ja) 2017-02-16 2020-03-12 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 統合失調症を処置する方法

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021451A (en) 1972-05-16 1977-05-03 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4036842A (en) 1972-05-16 1977-07-19 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4021452A (en) 1975-04-23 1977-05-03 American Cyanamid Company 2,5-Dihydro-2,5-dialkoxyfuran derivatives
US4127665A (en) 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives
FR2459239A1 (fr) 1979-06-20 1981-01-09 Logeais Labor Jacques Nouveaux derives amines du benzothiazole, leur procede de preparation et leur application en therapeutique
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
PT90001B (pt) 1988-03-16 1994-06-30 Zambeletti Spa L Processo para a preparacao de derivados heterociclicos de etilenodiamina
DE3827727A1 (de) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion
GB8824400D0 (en) 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
GB8827479D0 (en) 1988-11-24 1988-12-29 Zambeletti Spa L Novel compounds
EP0416740A3 (en) 1989-08-08 1991-08-28 Beecham Group P.L.C. Novel compounds with renin-inhibiting activity
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
ZA912744B (en) 1990-03-23 1992-02-26 Zambeletti Spa L Pharmaceuticals
JPH049367A (ja) 1990-04-26 1992-01-14 Zeria Pharmaceut Co Ltd アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬
GB9018139D0 (en) 1990-08-17 1990-10-03 Pfizer Ltd Therapeutic agents
NZ240155A (en) 1990-10-29 1992-10-28 Ishihara Sangyo Kaisha Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions
DE4104257A1 (de) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen
GB9104839D0 (en) 1991-03-07 1991-04-17 Zambeletti Spa L Novel compounds
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
PH31294A (en) 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
JP3223277B2 (ja) 1992-04-10 2001-10-29 カシオ計算機株式会社 楽音制御装置
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
IT1255178B (it) 1992-06-26 1995-10-20 Pierrel Spa N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica
DE59308842D1 (de) 1992-12-02 1998-09-10 Ciba Geigy Ag Selektiv-herbizides Mittel
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
JP3163068B2 (ja) 1993-12-27 2001-05-08 日本建工株式会社 野縁取付け金具
FR2723091B1 (fr) 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
BR9908726A (pt) 1998-03-12 2000-11-21 Novo Nordisk As Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
BR9917047A (pt) 1998-12-14 2002-07-30 Fujisawa Pharmaceutical Co Composto de piperazina, método para prepará-lo, composição farmacêutica contendo-o e seu uso
AU776276B2 (en) 1999-01-19 2004-09-02 Neurosearch A/S Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
US6313309B1 (en) 1999-04-05 2001-11-06 Ortho-Mcneil Pharmaceutical, Inc. 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
WO2001019831A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
EP1214060A2 (en) 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
WO2001032610A1 (en) 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Urea derivative, process for producing the same, and medicine containing the urea derivative
US20020049223A1 (en) 1999-11-05 2002-04-25 Elmore Steven W. Quinoline and naphthyridine carboxylic acid antibacterials
AR030537A1 (es) 1999-11-05 2003-08-27 Abbott Lab Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
AU2001286191A1 (en) 2000-09-12 2002-03-26 Sankyo Company, Limited Quinolizine derivatives
JP2002179678A (ja) 2000-09-12 2002-06-26 Sankyo Co Ltd キノリジン化合物
DOP2002000386A (es) 2001-05-30 2002-12-15 Warner Lambert Co Agentes antibacterianos
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
AU2002302894A1 (en) 2001-06-19 2003-01-02 Warner-Lambert Company Llc Quinazolinediones as antibacterial agents
US20040180883A1 (en) 2001-07-11 2004-09-16 Jeremy Gilmore Pharmaceutical compounds with serotonin receptor activity
EP1409476B1 (en) 2001-07-11 2004-12-15 Eli Lilly And Company Pharmaceutical compounds with serotonin receptor activity
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
JP2003261566A (ja) 2002-03-11 2003-09-19 Sankyo Co Ltd キノリジンを含有する医薬
TW200930291A (en) 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
US7778779B2 (en) 2002-10-16 2010-08-17 Isis Innovation Limited Method of identifying a chemical entity which is a hydroxylase modulator
CN101353321A (zh) 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
EP1587482A4 (en) 2003-01-31 2010-08-25 Technion Res & Dev Foundation INFLAMMATORY COMPOSITIONS AND ITS USES
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
JP2004269449A (ja) 2003-03-11 2004-09-30 Ishihara Sangyo Kaisha Ltd ベンズアミド誘導体、それらの製造方法及びそれらを含有する有害生物防除剤
US20070154534A1 (en) 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
WO2004087680A1 (en) 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Novel quinazoline derivatives and methods of treatment related to the use thereof
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
DE102004004974A1 (de) 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
JP2006117568A (ja) 2004-10-20 2006-05-11 Mitsubishi Pharma Corp チオフェン環を有する新規アミド誘導体及びその医薬としての用途
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
WO2007001939A1 (en) 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
KR20080030630A (ko) 2005-06-27 2008-04-04 이 아이 듀폰 디 네모아 앤드 캄파니 전기 전도성 중합체 조성물
BRPI0615524A2 (pt) 2005-07-11 2010-04-06 Devgen Nv derivados da amida como inibidores da quinase
US8846742B2 (en) 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
JP2009528999A (ja) 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド Ｃｂ１アンタゴニストおよび逆アゴニスト
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
JPWO2007126041A1 (ja) 2006-04-28 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾイソオキサゾール化合物
AU2007305269A1 (en) 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20100137294A1 (en) 2006-11-15 2010-06-03 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP1982987A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Spiro-pyrano-pyrazole derivatives
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
ES2469824T3 (es) 2007-11-21 2014-06-20 Janssen Pharmaceutica N.V. Espiropiperidinas para su uso como inhibidores de la triptasa
US7973051B2 (en) 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
JPWO2009072621A1 (ja) 2007-12-07 2011-04-28 日産化学工業株式会社 置換ジヒドロアゾール化合物及び有害生物防除剤
WO2009085256A1 (en) 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
CN101759710B (zh) 2008-10-06 2011-10-05 山东轩竹医药科技有限公司 含有取代的氮杂环的头孢菌素衍生物
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
DK2501704T3 (da) 2009-11-16 2013-10-14 Lilly Co Eli Spiropiperidinforbindelser som oral-1-receptorantagonister
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
WO2011081205A1 (ja) 2009-12-28 2011-07-07 一般社団法人ファルマＩｐ １，３，４－オキサジアゾール－２－カルボキサミド化合物
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
JP2013525368A (ja) 2010-04-23 2013-06-20 キネタ・インコーポレイテツド 抗ウイルス性化合物
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
CN102731574B (zh) 2011-03-30 2016-03-02 中国人民解放军军事医学科学院毒物药物研究所 噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
CN106537488B (zh) 2014-07-23 2019-06-07 夏普株式会社 显示装置及其驱动方法
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
JP2021513972A (ja) 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法
CA3122261A1 (en) 2018-12-06 2020-06-11 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
EP4214212A1 (en) 2020-09-16 2023-07-26 Teva Pharmaceuticals International GmbH Solid state forms of sep-363856 and process for preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507602A (ja) 2017-02-16 2020-03-12 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 統合失調症を処置する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Neuropsychopharmacology，2019年，Vol. 44，pp. 494-495，DOI: 10.1038/s41386-019-0547-9
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS，2019年，Vol. 371，pp. 1-14，DOI: 10.1124/jpet.119.260281
精神経誌，2018年，Vol. 120, No. 7，pp. 564-569

Also Published As

Publication number Publication date
JP2026035701A (ja) 2026-03-04
CN115734785A (zh) 2023-03-03
EP4135690A1 (en) 2023-02-22
US20240366559A1 (en) 2024-11-07
KR20230003503A (ko) 2023-01-06
WO2021211489A1 (en) 2021-10-21
EP4736951A2 (en) 2026-05-06
ZA202211311B (en) 2025-12-17
MX2022012833A (es) 2022-11-07
AU2021257786A1 (en) 2022-11-03
EP4135690B1 (en) 2026-03-25
US20210315859A1 (en) 2021-10-14
DK4135690T3 (da) 2026-04-07
IL297248A (en) 2022-12-01
US11738002B2 (en) 2023-08-29
JP2023523569A (ja) 2023-06-06
CA3180115A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP2026035701A (ja) 神経学的および精神障害の治療方法
US20240350453A1 (en) Methods of treating neurological and psychiatric disorders
JP7069253B2 (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2004517112A (ja) 新規薬物コンビネーション
CA2641917A1 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
US20220096444A1 (en) Prophylactic or therapeutic agent for delirium
CA3213576A1 (en) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
JP5553955B2 (ja) 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ
JP2012508186A (ja) むずむず脚症候群および睡眠障害の治療
HK40057761A (en) Methods of treating neurological and psychiatric disorders
US20080139615A1 (en) Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof
CN120051276A (zh) 减少对神经精神病学治疗的身体依赖性的方法
HK40000275A (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251126

R150 Certificate of patent or registration of utility model

Ref document number: 7781768

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150